Australia's most trusted
source of pharma news
Monday, 04 May 2026
Posted 4 May 2026
The PBAC will be haggling over price in its May Intracycle Meeting, and revisiting a drug it deferred four years ago.
Pfizer is headed back to the Committee with a revised pricing proposal for tyrosine kinase inhibitor Tukysa in Stage IV HER-2+ breast cancer after failing to come to an agreement with the Government following a positive PBAC recommendation in November last year, with the listing process currently marked as 'ceased'.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.